Search

Displaying results 5831 - 5840 of 10000 in total
  1. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.

  2. Drug

    GSK-923295

    go.drugbank.com/drugs/DB06097
    Investigational

    GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline … GSK-923295 is the first drug candidate to enter human clinical trials that specifically targets CENP-E and is currently in Phase I human clinical trials being conducted by GSK.

  3. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  4. Drug

    AER001

    go.drugbank.com/drugs/DB05078
    Investigational

    AER001, an IL4/13 receptor antagonist for severe asthma and eczema currently in Phase 2 studies.

  5. Drug

    Silibinin

    go.drugbank.com/drugs/DB09298
    Investigational

    Silibinin is presented as a mixture of two diastereomers, silybin A and silybin B, which are found in an approximately equimolar ratio. … Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins.

    Categories: Compounds used in a research, industrial, or household settingProducts: SILIMARINA 150 MG, HEPABIONTAGRAGEAS 150 MG
  6. Drug

    DT-DEC01

    go.drugbank.com/drugs/DB19433
    Experimental

    DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.

  7. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]

  8. Drug

    mRNA-3927

    go.drugbank.com/drugs/DB17669
    Investigational

    Developed by Moderna Inc., it is being investigated for the treatment of propionic acidemia.[L45998] … mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid

  9. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.

  10. Drug

    KT-253

    go.drugbank.com/drugs/DB18487
    Investigational

    KT-253 is a selective heterobifunctional small molecule degrader of mouse double minute 2 (MDM2).